Full Text
P38 One Size Does Not Fit All: Calculating the Cost-Effectiveness of Multiple Indications of Pembrolizumab in the Netherlands

Abstract

Authors

F Verbeek C van Gils R Heine C Uyl-De Groot

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×